Kolon TissueGene, Inc. (KOSDAQ:950160)

South Korea flag South Korea · Delayed Price · Currency is KRW
80,000
-2,100 (-2.56%)
At close: Dec 5, 2025
307.12%
Market Cap 6.66T
Revenue (ttm) 5.08B
Net Income (ttm) -87.46B
Shares Out 83.22M
EPS (ttm) -1,074.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 989,505
Average Volume 1,012,222
Open 82,100
Previous Close 82,100
Day's Range 76,400 - 82,600
52-Week Range 19,860 - 88,700
Beta -0.89
RSI 71.48
Earnings Date n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 29
Stock Exchange KOSDAQ
Ticker Symbol 950160
Full Company Profile

Financial Performance

In 2024, Kolon TissueGene's revenue was 5.07 billion, an increase of 36.90% compared to the previous year's 3.71 billion. Losses were -33.80 billion, 96.2% more than in 2023.

Financial Statements

News

There is no news available yet.